<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>2519400</identifier>
<setSpec>0034-9887</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Gonz√°lez, R</dc:author>
<dc:author>Marchesse, M</dc:author>
<dc:author>Fajuri, A</dc:author>
<dc:author>Serrat, H</dc:author>
<dc:author>Arriagada, C</dc:author>
<dc:description xml:lang="en">Verapamil is a calcium channel blocker ideally suited for the treatment of A-V nodal reciprocating supraventricular tachycardia. Most types of ventricular tachycardia are refractory to treatment with verapamil since they depend on sodium channels. However, a few cases of recurrent ventricular tachycardia are refractory to Type I antiarrhythmic agents and may respond to verapamil. We report 2 such cases.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>1989 Apr </dc:date>
<dc:title xml:lang="es">Taquicardia ventricular recurrente idiopatica: rol del verapamil en el tratamiento.</dc:title>
<dc:title xml:lang="en">[Idiopathic recurrent ventricular tachycardia: role of verapamil in its treatment].</dc:title>
<dc:publisher>Revista medica de Chile</dc:publisher>
</metadata>
</record>
</pubmed-document>
